Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. The companys Advanced Connectivity Solutions segment offers circuit materials and solutions for connectivity applications in wireless communications infrastructure, automotive, connected devices, wired infrastructure, consumer electronics, and aerospace/defense. Its Elastomeric Material Solutions segment provides elastomeric material solutions for critical cushioning, sealing, impact protection, and vibration management applications, including general industrial, portable electronics, consumer goods, automotive, mass transportation, construction, and printing applications. The companys Power Electronics Solutions segment offers ceramic substrate materials for power module applications, laminated bus bars for power inverter and high power interconnect applications, and micro-channel coolers. Its Other segment provides elastomeric components for applications in ground transportation, office equipment, consumer, and other markets; elastomeric floats for level sensing in fuel tanks, motors, and storage tanks; and inverters for portable communications and automotive markets. The company also manufactures and sells polytetrafluoroethylene, polyethylene films, and pressure sensitive tapes, as well as specialty products for the industrial, aerospace, automotive, and electronics markets; and silicone products for various applications. Rogers Corporation was founded in 1832 and is headquartered in Chandler, Arizona.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Diversified Electronics
- Sub-Industry: N/A
- Symbol: VTX:ROG
- CUSIP: N/A
- Web: www.roche.com
- 50 Day Moving Avg: CHF 115.18
- 200 Day Moving Avg: CHF 99.55
- Trailing P/E Ratio: 27.48
- P/E Growth: 1.39
- Net Margins: 21.17%
- Return on Equity: 46.76%
- Return on Assets: 14.96%
Frequently Asked Questions for Roche Holding (VTX:ROG)
What is Roche Holding's stock symbol?
Roche Holding trades on the VTX under the ticker symbol "ROG."
Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?
13 brokerages have issued twelve-month price targets for Roche Holding's shares. Their forecasts range from CHF 215 to CHF 335. On average, they anticipate Roche Holding's stock price to reach CHF 271.42 in the next twelve months. View Analyst Ratings for Roche Holding.
Who are some of Roche Holding's key competitors?
Some companies that are related to Roche Holding include Partnership Assurance Group PLC (PA), Celgene (CELG), GlaxoSmithKline plc (GSK), Thermo Fisher Scientific (TMO), Biogen (BIIB), AstraZeneca plc (AZN), Aetna (AET), Shire PLC (SHP), Baxter International (BAX), Alexion Pharmaceuticals (ALXN), Zoetis (ZTS), Laboratory Corp. of America Holdings (LH), Hospira (HSP), Smith & Nephew plc (SN), Universal Health Services (UHS), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX) and United Therapeutics (UTHR).
Who are Roche Holding's key executives?
MarketBeat Community Rating for Roche Holding (VTX ROG)MarketBeat's community ratings are surveys of what our community members think about Roche Holding and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Roche Holding's management team includes the folowing people:
- Severin Schwan, Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director
- Alan Hippe, Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
- Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications
- Sophie Kornowski-Bonnet, Member of the Enlarged Corporate Executive Committee, Head Roche Partnering
- Osamu Nagayama, Member of the Enlarged Corporate Executive Committee, Chairman and Chief Executive Officer Chugai
- John C. Reed M.D., Ph.D., Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
- Michael David Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
- Cristina A. Wilbur, Member of the Executive Committee, Head Group Human Resources
- Urs Jaisli, Chief Compliance Officer
- Gottlieb A. Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors
Consensus Ratings for Roche Holding (VTX:ROG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 5 Hold Ratings, 7 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.46)|
|Consensus Price Target: ||CHF 271.42|
Analysts' Ratings History for Roche Holding (VTX:ROG)
(Data available from 8/24/2015 forward)
|8/15/2017||Berenberg Bank||Set Price Target||Buy||CHF 273|
|8/8/2017||Goldman Sachs Group, Inc. (The)||Set Price Target||Buy||CHF 335|
|7/28/2017||Deutsche Bank AG||Set Price Target||Neutral||CHF 260|
|7/28/2017||J P Morgan Chase & Co||Reiterated Rating||Buy|
|7/27/2017||Sanford C. Bernstein||Set Price Target||Buy||CHF 284|
|7/26/2017||Morgan Stanley||Set Price Target||Neutral||CHF 260|
|7/12/2017||Jefferies Group LLC||Set Price Target||Buy||CHF 275|
|7/11/2017||HSBC Holdings plc||Set Price Target||Sell||CHF 215|
|7/11/2017||Kepler Capital Markets||Set Price Target||Neutral||CHF 235|
|7/5/2017||Citigroup Inc.||Reiterated Rating||Buy|
|6/29/2017||Societe Generale||Set Price Target||Neutral||CHF 275|
|6/20/2017||BNP Paribas||Set Price Target||Neutral||CHF 250|
|6/13/2017||Barclays PLC||Set Price Target||Buy||CHF 305|
Earnings History for Roche Holding (VTX:ROG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Roche Holding (VTX:ROG)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Roche Holding (VTX:ROG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Roche Holding (VTX:ROG)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Roche Holding (VTX:ROG)
Latest Headlines for Roche Holding (VTX:ROG)